within Pharmacolibrary.Drugs.ATC.B;

model B01AD10
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00065,
    adminDuration  = 600,
    adminMass      = 24 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.017,
    k12             = 20,
    k21             = 20
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AD10</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Drotrecogin alfa (activated) is a recombinant form of human activated protein C, previously used for the treatment of severe sepsis with high risk of death. It acts by exhibiting antithrombotic, profibrinolytic and anti-inflammatory properties. The drug was withdrawn from the market due to lack of demonstrated efficacy and concerns about safety, particularly bleeding risk.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with severe sepsis treated with intravenous drotrecogin alfa (activated).</p><h4>References</h4><ol><li><p>Lyseng-Williamson, KA, &amp; Perry, CM (2002). Drotrecogin alfa (activated). <i>Drugs</i> 62(4) 617–632. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200262040-00006&quot;>10.2165/00003495-200262040-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11893230/&quot;>https://pubmed.ncbi.nlm.nih.gov/11893230</a></p></li><li><p>Raggio, MJ, &amp; Morris, PE (2004). Drotrecogin alfa. <i>Drugs of today (Barcelona, Spain : 1998)</i> 40(6) 517–538. DOI:<a href=&quot;https://doi.org/10.1358/dot.2004.40.6.850484&quot;>10.1358/dot.2004.40.6.850484</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15349131/&quot;>https://pubmed.ncbi.nlm.nih.gov/15349131</a></p></li><li><p>Macias, WL, et al., &amp; Small, DS (2002). Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. <i>Clinical pharmacology and therapeutics</i> 72(4) 391–402. DOI:<a href=&quot;https://doi.org/10.1067/mcp.2002.128148&quot;>10.1067/mcp.2002.128148</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12386641/&quot;>https://pubmed.ncbi.nlm.nih.gov/12386641</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AD10;
